Vilket är priset för MGC Pharmaceuticals Limited (MXC)

Priset för MGC Pharmaceuticals Limited (MXC) är $0.27239819

Vilket är marknadsvärdet för MGC Pharmaceuticals Limited (MXC)

Marknadsvärdet för MGC Pharmaceuticals Limited (MXC) är $330.42K

MGC Pharmaceuticals Limited (MXC) Pris och Marknadsvärde

MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.

Pris för MXC	Tillgång B	Marknadsvärdet för B	Resultat
$4,509,100 $330.42K	NVDA	$5.470T	+1,655,333,783.30%
$3,682,664 $330.42K	AAPL	$4.467T	+1,351,941,256.29%
$3,441,374 $330.42K	GOOG	$4.174T	+1,263,361,352.97%
$3,050,352 $330.42K	MSFT	$3.700T	+1,119,813,600.87%
$2,353,127 $330.42K	AMZN	$2.854T	+863,855,380.45%

Pris för MXC

Tillgång B

Marknadsvärdet för B

Resultat

$4,509,100 $330.42K